You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Scipher will use the proceeds to further commercialize PrismRA, a molecular test intended to guide treatment decisions for patients with rheumatoid arthritis.
The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.
The company's two largest investors will purchase $25 million of its common shares, with proceeds supporting ongoing test commercialization.
Researchers showed benefit from chemotherapy in patients classified as high risk by the test, independent of their EGFR mutation status.
Investigators are conducting a prospectively designed, retrospective study of archived material from the NeoTRIPaPDL1 triple negative breast cancer trial.
The investment bank said that the company's noninvasive genomic test for melanoma detection could capture a large market currently served by invasive biopsies.
The gene expression test retrospectively identified rheumatoid arthritis patients significantly less likely to respond to TNF inhibitor therapy.
OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.
The decision comes after Myriad requested expanded coverage for women with breast cancer seeking information about extending endocrine therapy.
The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.